Efficacy and safety of JAK inhibitors in the treatment of moderate to severe atopic dermatitis in adults: a Systematic Review of the Literature
DOI:
https://doi.org/10.56183/iberojhr.v4i2.641Palavras-chave:
JAK inhibitors, efficacy, safety, moderate to severe atopic dermatitis, adults.Resumo
Background: Atopic dermatitis (AD)_ chronic inflammatory skin disorder, has affected the global population. Specifically, it is seen as more common in children about 10-20% prevalence in children’s and 2% among adults. Traditional treatments are insufficient for moderate to severe cases and necessitate new therapeutic options. Janus kinase (JAK) inhibitors is promising class of drugs due to their ability to modulate key inflammatory pathways involved in AD. Methodology: Systematic review was conducted using Cochrane Library database, PubMed, and Embase. Keywords and MeSH terms identified studies focusing on adult patients with moderate to severe AD. Inclusion criteria encompassed studies evaluating efficacy and safety of JAK inhibitors. Data extraction was performed using standardized forms, Cochrane Risk of Bias Tool conducted. Most of the articles are selected which are published in 2024 to keep our research up-to-date. Results: We have analyzed data from several studies evaluating the efficacy and safety of JAK inhibitors, most commonly abrocitinib, upadacitinib, and baricitinib. They have shown efficacy in reducing eczema symptoms with EASI-75 response rates of up to 80% for upadacitinib and 71% for abrocitinib. Higher doses of JAK inhibitors raised safety concerns like heart diseases, infections, and acne, but the standard recommended dose stood beneficial in reducing eczema. Conclusion: JAK inhibitors are advancements in the treatment of moderate to severe atopic dermatitis. They offer substantial symptom relief and improved quality of life.
Referências
Pareek, A., Kumari, L., Pareek, A., Chaudhary, S., Ratan, Y., Janmeda, P., Chuturgoon, S., & Chuturgoon, A. (2024). Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives. Cells, 13(5), 425. https://doi.org/10.3390/cells13050425
Hartmane, I. (2024). Study of Genetic Mutations and Their Association With the Development of Atopic Dermatitis and Other Skin Diseases. Plastic and Aesthetic Nursing, 44(3), 200-209.
Bhatt, M., Lal, K., & Silverberg, N. (2024). Special Considerations in Atopic Dermatitis in Young Children. Dermatologic Clinics.
Čelakovská, J., Čermákova, E., Boudková, P., Andrýs, C., & Krejsek, J. (2024). The association between expression of CD200 on B lymphocytes and the count of eosinophils and basophils in atopic dermatitis patients with and without dupilumab therapy–Pilot study. International Immunopharmacology, 132, 112023.
Afshari, M., Kolackova, M., Rosecka, M., Čelakovská, J., & Krejsek, J. (2024). Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Frontiers in Immunology, 15, 1361005.
Szalus, K., & Trzeciak, M. (2024). The Role of Collagens in Atopic Dermatitis. International Journal of Molecular Sciences, 25(14), 7647
Wu, J., Li, L., Zhu, Q., Zhang, T., Miao, F., Cui, Z., ... & Chen, Z. (2024). JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis. Biomedicine & Pharmacotherapy, 171, 116167.
Kim, R. W., Lam, M., Abuabara, K., Simpson, E. L., & Drucker, A. M. (2024). Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. American Journal of Clinical Dermatology, 25(2), 179-193.
Bonelli, M., Kerschbaumer, A., Kastrati, K., Ghoreschi, K., Gadina, M., Heinz, L. X., ... & Laurence, A. (2024). Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story. Annals of the Rheumatic Diseases, 83(2), 139-160.
Shah, H., Eckembrecher, F. J., Eckembrecher, D. G., & Nouri, K. (2024). Current and emerging immunobiologic therapies for atopic dermatitis. Drugs & Therapy Perspectives, 1-12.
Liu, M., Gao, Y., Yuan, Y., Zheng, L., Yao, L., Ge, L., Wang, Q., Yang, K., Zheng, Q., Cui, Y., Wang, J., Zhang, J., & Tian, J. (2024, May 17). Janus kinase (JAK) inhibitors in the treatment of moderate-to-severe atopic dermatitis (eczema): Systematic review and network meta-analysis
Le, M., Berman-Rosa, M., Ghazawi, F. M., Bourcier, M., Fiorillo, L., Gooderham, M., Guenther, L., Hanna, S., Hong, H. C., Landells, I., Lansang, P., Marcoux, D., Wiseman, M. C., Yeung, J., Lynde, C., & Litvinov, I. V. (2021). Systematic Review on the Efficacy and Safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.682547
Iznardo, H., Roé, E., Serra-Baldrich, E., & Puig, L. (2023). Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics, 15(2), 385. https://doi.org/10.3390/pharmaceutics15020385
Iznardo, H., Roé, E., Serra-Baldrich, E., & Puig, L. (2023). Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics, 15(2), 385. https://doi.org/10.3390/pharmaceutics15020385
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022). A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics, 14(5), 1001.
Munera-Campos, M., & Carrascosa, J. M. (2023). [Translated article] Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives. Actas dermo-sifiliograficas, 114(8), T680-T707.
Bieber, T., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C., Pink, A. E., ... & Valdez, H. (2021). Abrocitinib versus placebo or dupilumab for atopic dermatitis. New England Journal of Medicine, 384(12), 1101-1112.
Simpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., ... & Rojo, R. (2020). Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet, 396(10246), 255-266.
Gooderham, M. J., Forman, S. B., Bissonnette, R., Beebe, J. S., Zhang, W., Banfield, C., ... & Peeva, E. (2019). Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA dermatology, 155(12), 1371-1379.
Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C., & Rojo, R. (2020). Efficacy and safety of Abrocitinib in patients with Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 156(8), 863. https://doi.org/10.1001/jamadermatol.2020.1406
Bieber, T., Reich, K., Paul, C., Tsunemi, Y., Augustin, M., Lacour, J., Ghislain, P., Dutronc, Y., Liao, R., Yang, F. E., Brinker, D., DeLozier, A. M., Meskimen, E., Janes, J. M., & Eyerich, K. (2022). Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). British Journal of Dermatology/British Journal of Dermatology, Supplement, 187(3), 338–352. https://doi.org/10.1111/bjd.21630
Np, M. Y., & Ms, A. N. P. (2024, January 30). The future of AD treatment. HCP Live. https://www.hcplive.com/view/the-future-of-ad-treatment
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Fernanda De Las Mercedes López Naveda, Akemi Rocío Plaza Alcívar, Irina Talia Guzmán Chávez, Ana Karina Guamán Cevallos, Anthony Jesús Pastrana Villares, Ana Gabriela Castro Bojorque
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
